Pharmaceutical

CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio

CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.

Aug 2, 2023 - 20:00
CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio
CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.
Read the original article

Tags:

Previous Article

STAT+: Pharmalittle: House Republicans and Democrats duel over drug shortages; F...

Next Article

Atantares raises $13.9m in pre-Series A funding to develop molecular chips

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA raises alarm about weight-gain supplement apetamin

FDA raises alarm about weight-gain supplement apetamin

May 6, 2023

Opinion: Gaza, Ukraine, and other conflicts could be accelerating antibiotic resistance

Opinion: Gaza, Ukraine, and other conflicts could be ac...

Dec 29, 2023

STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year

STAT+: Pharmalittle: FDA OKs new kind of drug to treat ...

May 15, 2023